Abstract: Disseminated leishmaniasis is a severe and emerging form of American tegumentary leishmaniasis. Disseminated leishmaniasis is defined by the presence of more than 10 polymorphic cutaneous lesions, distributed over more than two noncontiguous parts of the body. Nasal mucosal involvement is observed in almost half of cases. Disseminated leishmaniasis patients present with a decreased production of Th1 cytokines in the peripheral blood due to the attraction of leishmaniaactivated T cells to the multiple cutaneous lesions. Disseminated leishmaniasis development is poorly understood and is related to a complex network involving environmental, host immune response, and parasite factors, in which L. braziliensis polymorphism plays an important role. Disseminated leishmaniasis is a challenging disease to cure, presenting a high failure rate of 75% to pentavalent antimony therapy. Despite its importance and severity, this form of American tegumentary leishmaniasis has been poorly studied and documented, deserving greater attention from professionals working in endemic areas.
INTRODUCTION
The leishmaniases make up a heterogeneous group of di- In recent decades, a significant increase in the incidence of DL has been observed in northeastern Brazil. 5 This is a worrying factor due to the aggressiveness of this little studied and little known form of leishmaniasis. Because it is an endemic long-term and difficult-to-treat disease, DL is considered a serious public health problem in neglected populations. 
EPIDEMIOLOGY

PATHOGENESIS
Parasitic factors
The protozoan Leishmania is an obligate intracellular parasite mainly of macrophages, transmitted from animals to humans by several species of sandflies, especially of the genus Lutzomyia in Brazil.
14 Although DL can be caused by more than one species of In situ immune response in DL is characterized by IFNγ, TNFα, CCL2, CCL3, CCL11, and CXCL10 expression in much the same way as in localized CL, whereas CXCL9 is produced in greater quantity by peripheral blood mononuclear cells from patients with DL compared to patients with CL. 20 CXCL9 is an IFNγ-induced chemokine associated with recruitment and proliferation of T lymphocytes. 21 These data suggest that a decrease in Th1 response in the peripheral blood of patients with DL is due to the attraction of Leishmania-specific T cells towards multiple cutaneous lesions. Therefore, the preserved tissue immune response in DL may explain the absence or low number of parasites in the lesions, as well as the development of ulcers similar to those observed in CL.
CLINICAL MANIFESTATIONS
In DL, the eruption and spread event occurs about 2-6 weeks after the initial ulcerated lesion. Several patients report systemic symptoms during this period, most commonly fever, asthenia, chills, malaise, and nausea, suggesting a process of parasitic dissemination, preferentially via the hematogenous route. The presence of lymphadenopathy in various body regions may occur during the dissemination phase in some patients. for cure, which can take several months to be achieved. All these factors increase the impact of the disease, with significant socio-economic repercussions on a low-income population with few resources. 14 One option for future use may be miltefosine (MF), an oral drug that interacts with intracellular signaling pathways and inhibits phospholipid and sterol biosynthesis. 28 It was the first oral drug
LABORATORY DIAGNOSIS
The diagnosis of DL is based on the clinical characteristics already described. Laboratory confirmation is based on Montenegro test, histopathological examination, and identification of the parasi-approved for the treatment of visceral leishmaniasis in India, and has been used since 2002. 29 Several studies have evaluated the efficacy of MF in the treatment of CL, with results that vary according to the Leishmania species and the geographic region of the study. [30] [31] [32] [33] Unfortunately, MF is still not available in Brazil, despite its proven efficacy and safety in the treatment of CL caused by L. braziliensis (75% cure) and L. guyanensis (71% cure), the two most prevalent species in the country. 32, 33 Thus, although there are only a few case reports of DL patients treated successfully with MF alone or in combination with liposomal amphotericin, MF is likely to be a new therapy option for DL. 34, 35 Considering the therapeutic difficulty in DL cases, an im- a) The parenteral use of glucantime at the maximum dose recommended for 30 days shows a cure rate above 50% b) In the occurrence of mucosal lesions, the first treatment option should be amphotericin B even in elderly patients or patients with kidney disease c) Oral therapy with Miltefosine induces healing in more than 70% of patients d) Liposomal amphotericin B shows a high cure rate mainly at doses above 35mg/kg
